<!DOCTYPE html>
<!--
	Forty by HTML5 UP
	html5up.net | @ajlkn
	Free for personal and commercial use under the CCA 3.0 license (html5up.net/license)
-->
<html>

<head>
	<title>Official Documents, Media Coverage and Research Articles | Forgotten Lives UK</title>
	<meta charset="utf-8" />
	<meta name="viewport" content="width=device-width, initial-scale=1, user-scalable=no" />
	<!--[if lte IE 8]><script src="/assets/js/ie/html5shiv.js"></script><![endif]-->
	<link rel="stylesheet" href="/assets/css/main.css" />
	<!--[if lte IE 9]><link rel="stylesheet" href="/assets/css/ie9.css" /><![endif]-->
	<!--[if lte IE 8]><link rel="stylesheet" href="/assets/css/ie8.css" /><![endif]-->
</head>


<body>
    <script type="text/javascript">document.body.classList.add("is-loading");</script>

    <!-- Wrapper -->
<div id="wrapper">

<!-- Header -->
<header id="header">
	<a href="https://forgottenlives.uk//" class="logo"><strong>Forgotten Lives UK</strong> <span>A Patient Campaigning Group</span></a>
	<nav>
		<a href="#menu">Menu</a>
	</nav>
</header>

<!-- Menu -->
<nav id="menu">
	<ul class="links">
		<li><a href="/500k/">The Forgotten 500k Campaign</a></li>
        
		    
		
		    
		
		    
		
		    
		
		    
		
		    
		
		    
		
		    
		
		    
		
		    
		
		    
		
		    
		
		    
		
		    
		        <li><a href="https://forgottenlives.uk//">Home</a></li>
	    	
		
		    
		
		
		    
		        <li><a href="https://forgottenlives.uk/2_campaign.html">Help us Campaign</a></li>
		    
		
		    
		        <li><a href="https://forgottenlives.uk/3_evusheld.html">Learn more about monoclonal antibodies</a></li>
		    
		
		    
		
		    
		        <li><a href="https://forgottenlives.uk/4_media.html">Official Documents, Media Coverage and Research Articles</a></li>
		    
		
		    
		        <li><a href="https://forgottenlives.uk/4_patients.html">Patient stories</a></li>
		    
		
		    
		        <li><a href="https://forgottenlives.uk/5_support.html">Support for Shielders</a></li>
		    
		
		    
		        <li><a href="https://forgottenlives.uk/6_clinical.html">Charity Letter and Clinical Consultation</a></li>
		    
		
		    
		        <li><a href="https://forgottenlives.uk/7_overseas.html">What would it mean?</a></li>
		    
		
		    
		        <li><a href="https://forgottenlives.uk/all_posts.html">All posts</a></li>
		    
		
		    
		
		    
		
		    
		
		    
		
		    
		
	</ul>
	<ul class="actions vertical">
		<li><a href="2_campaign.html" class="button special fit">Get Started</a></li>
	</ul>
</nav>


        <section id="banner" class="style2">
            <div class="inner">
                <span class="image">
                    <img src="/assets/images/media.png" alt="">
                </span>
                <header class="major">

                    <h1>Official Documents, Media Coverage and Research Articles</h1>

                </header>
                <div class="content">

                    Read about Forgotten Lives UK in the media.

                </div>
            </div>
        </section>

    <div class="content">
        <div class="inner">
            <p>This page contains media coverage, research articles, preprints, medical opinion pieces, and policy documents. If we are missing items, please email them to <a href="mailto:martin@eve.gd">the maintainer</a>.</p>

<h2 id="documents">Documents</h2>
<p>These are documents issued or prepared by Evusheld for the UK or by charity partners with whom we work, here released in the interests of transparency.</p>

<ul>
  <li>Evusheld for the UK. 2022. ‘<a href="/assets/downloads/2023-03-23-Letter-to-PM.pdf">Letter to the UK Prime Minister</a>’. 23 March 2023.</li>
  <li>Evusheld for the UK. 2022. ‘<a href="/assets/downloads/2022-10-20-Private-Provision-Press-Release.pdf">UK Government Privatises Covid Response and Forces Vulnerable Immunocompromised Patients to Pay for Covid Drugs</a>’. 20 October 2022.</li>
  <li>Evusheld for the UK. 2022. ‘<a href="/assets/downloads/2022-10-09-NICE-Submission.pdf">Submission to NICE consultation COVID-19 (prevention) - tixagevimab–cilgavimab ID6136</a>’. 09 October 2022.</li>
  <li>Blood Cancer UK. 2022. ‘<a href="/assets/downloads/2022-10-04-Letter-to-Coffey.pdf">Letter to the Secretary of State for Health</a>’. 04 October 2022.</li>
  <li>Evusheld for the UK. 2022. ‘<a href="/assets/downloads/2022-09-16-Response-to-SoS.pdf">Response Letter to the New Secretary of State for Health</a>’. 20 September 2022.</li>
  <li>Evusheld for the UK. 2022. ‘<a href="/assets/downloads/2022-08-23-Evusheld-Charity-Letter-to-Barclay.pdf">Joint Charity Letter to Secretary of State for Health</a>’. 23 August 2022.</li>
  <li>Evusheld for the UK. 2022. ‘<a href="/assets/downloads/2022-08-12-DHSC-Response.pdf">Response to DHSC Shelving Plans for Evusheld in Winter 2022</a>’. 12 August 2022.</li>
  <li>Evusheld for the UK. 2022. ‘<a href="/assets/downloads/NICE-Scoping.pdf">Response to NICE Scoping Consultation: Tixagevimab–cilgavimab for preventing COVID-19, ID6136</a>’. 11 August 2022.</li>
  <li>Evusheld for the UK. 2022. ‘<a href="/assets/downloads/2022-08-10-Press-Release.pdf">Department of Health Plans to Deny Lifesaving Treatment to Vulnerable Patients</a>’. 10 August 2022.</li>
  <li>Evusheld for the UK. 2022. ‘<a href="/assets/downloads/2022-06-21-Press-Release.pdf">UK “Outlier” in Not Protecting 500,000+ Vulnerable Patients with New Lifesaving Drug. AstraZeneca Denies Government Claims of Further Testing</a>’. 21 June 2022.</li>
</ul>

<h2 id="selected-media-coverage">Selected Media Coverage</h2>
<p>These are articles in mainstream media/press releases about Evusheld in the UK, in reverse chronological order. It also includes statements from major UK charities on the drug.</p>

<ul>
  <li>Harris, Siobhan. ‘<a href="https://www.medscape.co.uk/viewarticle/medical-experts-ask-rethink-evusheld-2022a10021il">Medical Experts Ask for a Rethink on Evusheld</a>’. <em>Medscape UK</em>. Accessed 21 August 2022.</li>
  <li>Raphael, Therese, and Sam Fazeli. ‘<a href="https://www.washingtonpost.com/business/britain-needs-a-better-booster-strategy-for-covid/2022/08/19/99c04c2e-1f7c-11ed-9ce6-68253bd31864_story.html">Britain Needs a Better Booster Strategy for Covid</a>’. <em>Washington Post</em>, 19 August 2022.</li>
  <li>Mahase, Elisabeth. ‘<a href="https://doi.org/10.1136/bmj.o2021">Covid-19: UK Will Not Buy Evusheld Owing to “Insufficient Data” on Protection, Government Says</a>’. <em>BMJ</em> 378 (15 August 2022): o2021.</li>
  <li>Walsh, Fergus. ‘<a href="https://www.bbc.com/news/health-62516896">Covid: Evusheld Antibody Protection Ruled out for Most Vulnerable</a>’, <em>BBC News</em>, 12 August 2022, sec. Health.</li>
  <li>Davis, Nicola. ‘<a href="https://www.theguardian.com/world/2022/aug/12/uk-decision-not-to-buy-covid-drug-evusheld-disappoints-charities">UK Decision Not to Buy Covid Drug Evusheld Disappoints Charities</a>’. <em>The Guardian</em>, 12 August 2022, sec. World news.</li>
  <li>Gallagher, Paul. ‘<a href="https://inews.co.uk/news/health/evusheld-covid-uk-drug-prevent-high-risk-groups-vulnerable-people-1790926">Thousands of Vulnerable “in Limbo” as Government Rules out Buying Covid Protection Drug</a>’. <em>inews.co.uk</em>, 12 August 2022.</li>
  <li>Taylor, Phil. ‘<a href="https://pharmaphorum.com/news/dismay-as-uk-drags-its-heels-on-azs-covid-antibody-evusheld/">Dismay as UK “drags Its Heels” on AZ’s COVID Antibody Evusheld</a>’. <em>Pharmaphorum</em>, 12 August 2022.</li>
  <li>AstraZeneca. ‘<a href="https://www.astrazeneca.com/media-centre/statements/2022/update-to-evusheld-recommended-dosage-regimen-for-pre-exposure-prophylaxis-of-covid-19.html">Update to Evusheld Recommended Dosage Regimen for Pre-Exposure Prophylaxis of COVID-19</a>’, 14 July 2022.</li>
  <li>Sarcoidosis UK. ‘<a href="https://www.sarcoidosisuk.org/information-hub/evusheld/">SarcoidosisUK Evusheld Statement</a>’. <em>SarcoidosisUK</em>, 10 July 2022.</li>
  <li>Cardiomyopathy UK. ‘<a href="https://www.cardiomyopathy.org/news-blogs/latest-news/evusheld">A Statement on Evusheld</a>’. <em>Cardiomyopathy UK</em>, 8 July 2021.</li>
  <li>Davies, Joe. ‘<a href="https://www.msn.com/en-gb/health/medical/calls-for-uk-to-stock-up-on-covid-drug-that-slashes-illness-by-80percent/ar-AAZj9Mf">Calls for UK to Stock up on Covid Drug That Slashes Illness by 80%</a>’. <em>Daily Mail</em>, 7 July 2022.</li>
  <li>Lay, Kat. ‘<a href="https://www.thetimes.co.uk/article/calls-grow-for-government-to-order-covid-drug-to-boost-protection-for-vulnerable-h6x7gq229">Calls Grow for Government to Order Covid Drug to Boost Protection for Vulnerable</a>’. <em>The Times</em>, 6 July 2022, sec. news.</li>
  <li>Lennard, Lee. ‘<a href="/assets/downloads/2022-07-05-APPG.pdf">Consultation for an Independent Clinical Consensus Statement for Protective Measures for VGP</a>’. All-Party Parliamentary Group on Vulnerable Groups to Pandemics, 5 July 2022.</li>
  <li>Ennals, Ethan. ‘<a href="https://www.dailymail.co.uk/health/article-10976341/Will-Covid-drug-Evusheld-offered-vulnerable-Britons-dont-respond-vaccine.html">Will Covid Drug Evusheld Be Offered to Brits Who Don’t Respond to Jab?</a>’. <em>Mail Online</em>, 2 July 2022.</li>
  <li>Mullard, Asher. ‘<a href="https://doi.org/10.1038/d41586-022-01735-7">COVID Antibody Drugs Have Saved Lives — so Why Aren’t They More Popular?</a>’ <em>Nature</em> 606, no. 7916 (29 June 2022): 854–56.</li>
  <li>Sharp, Christopher. ‘<a href="https://www.express.co.uk/life-style/health/1629554/blood-cancer-uk-treatment-evusheld-covid">Blood Cancer UK Says Government “Needs to Do More” amid Battle for Evusheld</a>’. <em>Express.co.uk</em>, 26 June 2022.</li>
  <li>Shapiro, Lindsey. 2022. ‘<a href="https://multiplesclerosisnewstoday.com/news-posts/2022/06/10/evusheld-boosts-antibodies-against-covid-19-vaccinated-ms-patients/">Evusheld Boosts Antibodies Against COVID-19 in Vaccinated MS Patients</a>’. <em>Multiple Sclerosis News Today</em> (blog). 10 June 2022.</li>
  <li>‘<a href="https://www.zawya.com/en/press-release/companies-news/evusheld-significantly-prevented-covid-19-disease-progression-or-death-in-tackle-phase-iii-treatment-trial-appg120c">Evusheld Significantly Prevented COVID-19 Disease Progression or Death in Tackle Phase III Treatment Trial</a>’. 2022. <em>Zawya</em>. 10 June 2022.</li>
  <li>‘<a href="https://www.clinicaltrialsarena.com/news/astrazeneca-evusheld-covid-trial-2/">AstraZeneca’s Evusheld Prevents Disease Progression in Phase III Covid-19 Trial</a>’. 2022. <em>Clinical Trials Arena</em> (blog). 9 June 2022.</li>
  <li>AstraZeneca. 2022. ‘<a href="https://www.astrazeneca.com/media-centre/press-releases/2022/evusheld-significantly-prevented-covid-19-disease-progression-or-death-in-tackle-phase-iii-treatment-trial.html">Evusheld Significantly Prevented COVID-19 Disease Progression or Death in TACKLE Phase III Treatment Trial</a>’. 8 June 2022.</li>
  <li>Chudleigh, Hannah. 2022. ‘<a href="https://www.biospace.com/article/astrazeneca-s-evusheld-successfully-prevents-progression-to-severe-covid-19-/">AstraZeneca’s Evusheld Successfully Prevents Progression to Severe COVID-19</a>’. <em>BioSpace</em>. 8 June 2022.</li>
  <li>Kahn, Rachel. 2022. ‘<a href="https://bloodcancer.org.uk/news/evusheld-does-it-work-against-omicron/">Evusheld – Does It Work against Omicron?</a>’ <em>Blood Cancer UK</em>. 6 June 2022.</li>
  <li>Sharp, Christopher. 2022. ‘<a href="https://www.express.co.uk/life-style/health/1615894/covid-kidney-disease-immunosuppressed-exclusive/amp">Covid: Why the Threat of the Virus Still Haunts Those Who Are Immunosuppressed</a>’. Express, 29 May 2022.</li>
  <li>AstraZeneca. 2022. ‘<a href="https://www.astrazeneca.com/media-centre/medical-releases/evusheld-long-acting-antibody-combination-retains-neutralising-activity-omicron-variants-ba4-ba5-according-new-study-university-oxford.html">Evusheld Long-Acting Antibody Combination Retains Neutralising Activity against Omicron Variants BA.4 and BA.5, According to New Study from University of Oxford</a>’. 25 May 2022.</li>
  <li>Barnes, Oliver. 2022. ‘<a href="https://www.ft.com/content/fe03bc3b-a381-462d-b373-87dabde0a9ab">UK Accused of Leaving Covid Immunocompromised “out to Dry”</a>’. <em>Financial Times</em>, 4 May 2022.</li>
  <li>Kollewe, Julia. 2022. ‘<a href="https://www.theguardian.com/business/2022/apr/29/evusheld-covid-19-medicine-astrazeneca-immunosuppressed-vulnerable-uk">AstraZeneca Boss Calls for UK to Provide New Covid-19 Medicine to the Vulnerable</a>’. <em>The Guardian</em>, 29 April 2022, sec. Business.</li>
  <li>Ennals, Ethan. 2022. ‘<a href="https://www.dailymail.co.uk/health/article-10746187/Covid-19-Vulnerable-patients-denied-800-anti-viral-jab-unless-private.html">Covid 19: Vulnerable Patients Denied £800 Anti-Viral Jab Unless They Go Private</a>’. Daily Mail. 23 April 2022.</li>
  <li>AstraZeneca. 2022. ‘<a href="https://www.astrazeneca.com/media-centre/medical-releases/evusheld-long-acting-antibody-combination-retains-neutralising-activity-against-omicron-variants-including-ba2-in-new-independent-studies.html">Evusheld Long-Acting Antibody Combination Retains Neutralising Activity against Omicron Variants Including BA.2 in New Independent Studies</a>’. 21 March 2022.</li>
  <li>‘<a href="https://www.gov.uk/government/news/evusheld-approved-to-prevent-covid-19-in-people-whose-immune-response-is-poor">Evusheld Approved to Prevent COVID-19 in People Whose Immune Response Is Poor</a>’. 2022. GOV.UK. 17 March 2022.</li>
  <li>AstraZeneca. 2022. ‘<a href="https://www.astrazeneca.com/media-centre/press-releases/2022/astrazenecas-antibody-combination-evusheld-authorised-for-use-in-great-britain-for-pre-exposure-prophylaxis-prevention-of-covid-19.html">AstraZeneca’s Antibody Combination, Evusheld (Tixagevimab Co-Packaged with Cilgavimab) Authorised for Use in Great Britain for Pre-Exposure Prophylaxis (Prevention) of COVID-19</a>’. 17 March 2022.</li>
  <li>‘<a href="https://www.birmingham.ac.uk/news/latest/2022/01/covid-immunodeficiency-death-risk-infection.aspx">Individuals with Immunodeficiency at High Risk of Mortality Following SARS-CoV-2 Infection</a>’. 2022. University of Birmingham. 31 January 2022.</li>
</ul>

<h2 id="research-articles-preprints-medical-opinion-pieces-and-policy-documents-about-evusheld">Research Articles, Preprints, Medical Opinion Pieces, and Policy Documents about Evusheld</h2>
<p>These are formal research studies into the efficacy and dosage of Evusheld. These are arranged by alphabetical order of first author. We list here all articles (attempting a comprehensive literature review) rather than merely those with positive findings.</p>

<p>Articles marked [PREPRINT] have not necessarily been subject to <a href="https://en.wikipedia.org/wiki/Peer_review">peer review</a>.</p>

<ul>
  <li>‘<a href="https://secure.medicalletter.org/TML-article-1654d">COVID-19 Update: Hypersensitivity Reactions with Tixagevimab/Cilgavimab (Evusheld)</a>’. The Medical Letter on Drugs and Therapeutics 64, no. 1654 (11 July 2022): 112.</li>
  <li>‘<a href="https://secure.medicalletter.org/TML-article-1656b">COVID-19 Update: Dosing Interval for Tixagevimab/Cilgavimab (Evusheld)</a>’. <em>The Medical Letter on Drugs and Therapeutics</em>, 8 August 2022.</li>
  <li>ACTIV-3–Therapeutics for Inpatients with COVID-19 (TICO) Study Group. ‘<a href="https://doi.org/10.1016/S2213-2600(22)00215-6">Tixagevimab–Cilgavimab for Treatment of Patients Hospitalised with COVID-19: A Randomised, Double-Blind, Phase 3 Trial</a>’. <em>The Lancet Respiratory Medicine</em>, 8 July 2022.</li>
  <li>Aggarwal, Anupriya, Anouschka Akerman, Vanessa Milogiannakis, Mariana Ruiz Silva, Gregory Walker, Alberto Ospina Stella, Andrea Kindinger, et al. ‘<a href="https://doi.org/10.1016/j.ebiom.2022.104270">SARS-CoV-2 Omicron BA.5: Evolving Tropism and Evasion of Potent Humoral Responses and Resistance to Clinical Immunotherapeutics Relative to Viral Variants of Concern</a>’. <em>EBioMedicine</em> 84 (18 September 2022): 104270.</li>
  <li>Aisenberg, Gabriel M. ‘<a href="https://doi.org/10.7326/J22-0056">In Persons at Risk for Poor Vaccination Response or COVID-19 Exposure, Tixagevimab + Cilgavimab Reduced COVID-19</a>’. <em>Annals of Internal Medicine</em> 175, no. 8 (16 August 2022): JC92.</li>
  <li>Akerman, Anouschka, Vanessa Milogiannakis, Tyra Jean, Camille Esneau, Mariana Ruiz Silva, Timothy Ison, Christina Fichter, et al. ‘<a href="https://doi.org/10.1016/j.ebiom.2023.104545">Emergence and Antibody Evasion of BQ, BA.2.75 and SARS-CoV-2 Recombinant Sub-Lineages in the Face of Maturing Antibody Breadth at the Population Level</a>’. <em>EBioMedicine</em> 90 (30 March 2023): 104545.</li>
  <li>Akinosoglou, Karolina, Emmanouil-Angelos Rigopoulos, Georgia Kaiafa, Stylianos Daios, Eleni Karlafti, Eleftheria Ztriva, Georgios Polychronopoulos, Charalambos Gogos, and Christos Savopoulos. ‘<a href="https://doi.org/10.3390/v15010118">Tixagevimab/Cilgavimab in SARS-CoV-2 Prophylaxis and Therapy: A Comprehensive Review of Clinical Experience</a>’. <em>Viruses</em> 15, no. 1 (30 December 2022): 118.</li>
  <li>Alejo, Jennifer L., Jake D. Kim, Teresa Py Chiang, Robin K. Avery, Andrew H. Karaba, Alexa Jefferis, Daniel S. Warren, et al. ‘<a href="https://doi.org/10.1111/ctr.14913">Patient-Reported Outcomes after Tixagevimab and Cilgavimab Pre-Exposure Prophylaxis among Solid Organ Transplant Recipients: Safety, Effectiveness, and Perceptions of Risk</a>’. <em>Clinical Transplantation</em>, 18 January 2023, e14913.</li>
  <li>Alhumaid, Saad, Abbas Al Mutair, Jalal Alali, Nourah Al Dossary, Sami Hussain Albattat, Sarah Mahmoud Al HajjiMohammed, Fatimah Saad Almuaiweed, et al. ‘<a href="https://doi.org/10.3390/diseases10040118">Efficacy and Safety of Tixagevimab/Cilgavimab to Prevent COVID-19 (Pre-Exposure Prophylaxis): A Systematic Review and Meta-Analysis</a>’. <em>Diseases</em> 10, no. 4 (1 December 2022): 118.</li>
  <li>Al-Obaidi, Mohanad M., Ahmet B. Gungor, Sandra E. Kurtin, Ann E. Mathias, Bekir Tanriover, and Tirdad T. Zangeneh. ‘<a href="https://doi.org/10.1016/j.amjmed.2022.08.019">The Prevention of COVID-19 in High-Risk Patients Using Tixagevimab–Cilgavimab (Evusheld): Real-World Experience at a Large Academic Center</a>’. The American Journal of Medicine, 28 September 2022.</li>
  <li>Anmar, Al-Taie. ‘<a href="https://doi.org/10.1017/dmp.2022.150">Tixagevimab and Cilgavimab: Can We See More Recommendations for Monoclonal Antibodies Beyond COVID-19 Vaccination</a>’. <em>Disaster Medicine and Public Health Preparedness</em>, 8 June 2022, 1–2.</li>
  <li>Antonov, V. N., and G. L. Ignatova. ‘<a href="https://doi.org/10.26442/00403660.2023.03.202146">Efficacy and safety of patients immunization with chronic obstructive pulmonary disease with monoclonal antibodies</a>’. <em>Terapevticheskii Arkhiv</em> 95, no. 3 (26 April 2023): 243–47.</li>
  <li>Atluri, Kavya, Iris Aimlin, and Shitij Arora. ‘<a href="https://doi.org/10.3390/jcm11133838">Current Effective Therapeutics in Management of COVID-19</a>’. Journal of Clinical Medicine 11, no. 13 (1 July 2022): 3838.</li>
  <li>Aqeel, Faten, and Duvuru Geetha. ‘Tixagevimab and Cilgavimab (Evusheld) in Rituximab-Treated Antineutrophil Cytoplasmic Antibody Vasculitis Patients’. <a href="https://doi.org/10.1016/j.ekir.2022.08.019">Kidney International Reports</a>, 27 August 2022.</li>
  <li>Baloda, Vandana, Erin K. McCreary, Breana K. Goscicki, Michael R. Shurin, and Sarah E. Wheeler. ‘<a href="https://doi.org/10.1093/ajcp/aqac137">Tixagevimab Plus Cilgavimab Does Not Affect the Interpretation of Electrophoretic and Free Light Chain Assays</a>’. <em>American Journal of Clinical Pathology</em>, 5 December 2022, aqac137.</li>
  <li>Bender Ignacio, Rachel A., David A. Wohl, Rosalin Arends, Venkatesh Pilla Reddy, Ying Mu, Arzhang Cyrus Javan, Michael D. Hughes, et al. ‘<a href="https://doi.org/10.1002/cpt.2706">Comparative Pharmacokinetics of Tixagevimab/Cilgavimab (AZD7442) Administered Intravenously Versus Intramuscularly in Symptomatic SARS-CoV-2 Infection</a>’. <em>Clinical Pharmacology and Therapeutics</em>, 7 July 2022.</li>
  <li>Benotmane, Ilies, Aurélie Velay, Gabriela Gautier Vargas, Jérôme Olagne, Olivier Thaunat, Samira Fafi-Kremer, and Sophie Caillard. ‘<a href="https://doi.org/10.1016/j.kint.2022.05.008">Pre-Exposure Prophylaxis with 300 Mg Evusheld Elicits Limited Neutralizing Activity against the Omicron Variant</a>’. <em>Kidney International</em>, 24 May 2022, S0085-2538(22)00383-0.</li>
  <li>Benotmane, Ilies, Aurélie Velay, Gabriela Gautier Vargas, Jérôme Olagne, Augustin Obrecht, Noëlle Cognard, Francoise Heibel, et al. ‘<a href="https://doi.org/10.1111/ajt.17121">Breakthrough COVID-19 Cases despite Prophylaxis with 150 Mg of Tixagevimab and 150 Mg of Cilgavimab in Kidney Transplant Recipients</a>’. <em>American Journal of Transplantation</em>. Accessed 23 June 2022.</li>
  <li>Benotmane, Ilies, Aurélie Velay, Gabriela Gautier Vargas, Jérôme Olagne, Noëlle Cognard, Francoise Heibel, Laura Braun-Parvez, et al. ‘<a href="https://doi.org/10.1016/j.kint.2022.07.022">A Rapid Decline in the Anti-Receptor Binding Domain of the SARS-CoV-2 Spike Protein IgG Titer in Kidney Transplant Recipients after Tixagevimab-Cilgavimab Administration</a>’. <em>Kidney International</em> (13 August 2022).</li>
  <li>Bertrand, Dominique, Charlotte Laurent, Veronique Lemée, Ludivine Lebourg, Mélanie Hanoy, Frank Le Roy, Dorian Nezam, et al. ‘<a href="https://doi.org/10.1016/j.kint.2022.05.007">Efficacy of Anti-SARS-CoV-2 Monoclonal Antibody Prophylaxis and Vaccination on the Omicron Variant of COVID-19 in Kidney Transplant Recipients</a>’. <em>Kidney International</em> 102, no. 2 (August 2022): 440–42.</li>
  <li>Birabaharan, Morgan, Eddie Hill, Maedha Begur, David C. Kaelber, Thomas Cs Martin, and Sanjay R. Mehta. ‘<a href="https://doi.org/10.1093/cid/ciac894">Cardiovascular Outcomes after Tixagevimab and Cilgavimab Use for Pre-Exposure Prophylaxis against COVID-19: A Population-Based Propensity-Matched Cohort Study</a>’. <em>Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America</em>, 16 November 2022, ciac894.</li>
  <li>Boschi, Céline, Philippe Colson, Audrey Bancod, Valérie Moal, and Bernard La Scola. ‘<a href="https://doi.org/10.1093/cid/ciac143">Omicron Variant Escapes Therapeutic Monoclonal Antibodies (MAbs) Including Recently Released Evusheld®, Contrary to 8 Prior Main Variant of Concern (VOC)</a>’. <em>Clinical Infectious Diseases</em>, 16 February 2022, ciac143.</li>
  <li>Brady, Drugan K., Aashi R. Gurijala, Liyu Huang, Ali A. Hussain, Audrey L. Lingan, Olivia G. Pembridge, Brina A. Ratangee, Tristan T. Sealy, Kyle T. Vallone, and Thomas P. Clements. ‘<a href="https://doi.org/10.1111/febs.16662">A Guide to COVID-19 Antiviral Therapeutics: A Summary and Perspective of the Antiviral Weapons Against SARS-CoV-2 Infection</a>’. <em>The FEBS Journal</em>, 20 October 2022.</li>
  <li>Brady, Tyler, Tianhui Zhang, Kevin M. Tuffy, Nantaporn Haskins, Qun Du, Jia Lin, Gilad Kaplan, et al. ‘<a href="https://doi.org/10.1128/spectrum.01034-22">Qualification of a Biolayer Interferometry Assay to Support AZD7442 Resistance Monitoring</a>’. <em>Microbiology Spectrum</em> 10, no. 5 (22 August 2022): e01034-22.</li>
  <li>Bruel, Timothée, Jérôme Hadjadj, Piet Maes, Delphine Planas, Aymeric Seve, Isabelle Staropoli, Florence Guivel-Benhassine, et al. ‘<a href="https://doi.org/10.1038/s41591-022-01792-5">Serum Neutralization of SARS-CoV-2 Omicron Sublineages BA.1 and BA.2 in Patients Receiving Monoclonal Antibodies</a>’. <em>Nature Medicine</em> 28, no. 6 (June 2022): 1297–1302.</li>
  <li>Bruel, Timothée, Karl Stéfic, Yann Nguyen, Donatella Toniutti, Isabelle Staropoli, Françoise Porrot, Florence Guivel-Benhassine, et al. ‘<a href="https://doi.org/10.1016/j.xcrm.2022.100850">Longitudinal Analysis of Serum Neutralization of SARS-CoV-2 Omicron BA.2, BA.4, and BA.5 in Patients Receiving Monoclonal Antibodies</a>’. <em>Cell Reports</em>. Medicine, 17 November 2022, 100850.</li>
  <li>[PREPRINT] Bruel, Timothée, Karl Stéfic, Yann Nguyen, Donatella Toniutti, Isabelle Staropoli, Françoise Porrot, Florence Guivel-Benhassine, et al. ‘<a href="https://doi.org/10.1101/2022.08.12.22278699">Longitudinal Analysis of Serum Neutralization of SARS-CoV-2 Omicron BA.2, BA.4 and BA.5 in Patients Receiving Monoclonal Antibodies</a>’. <em>medRxiv</em>, 13 August 2022.</li>
  <li>Calabrese, Cassandra, Elizabeth Kirchner, Alexandra Villa-Forte, Rula A. Hajj-Ali, Brandon P. Moss, James P. Fernandez, and Leonard Calabrese. ‘<a href="https://doi.org/10.1136/rmdopen-2022-002557">Early Experience with Tixagevimab/Cilgavimab Pre-Exposure Prophylaxis in Patients with Immune-Mediated Inflammatory Disease Undergoing B Cell Depleting Therapy and Those with Inborn Errors of Humoral Immunity</a>’. <em>RMD Open</em> 8, no. 2 (1 September 2022): e002557.</li>
  <li>Cao, Yunlong, Weiliang Song, Lei Wang, Pan Liu, Can Yue, Fanchong Jian, Yuanling Yu, et al. ‘<a href="https://doi.org/10.1016/j.chom.2022.09.018">Characterization of the Enhanced Infectivity and Antibody Evasion of Omicron BA.2.75</a>’. <em>Cell Host &amp; Microbe</em>, 4 October 2022, S1931-3128(22)00511-X.</li>
  <li>Case, James Brett, Samantha Mackin, John M. Errico, Zhenlu Chong, Emily A. Madden, Bradley Whitener, Barbara Guarino, et al. ‘<a href="https://doi.org/10.1038/s41467-022-31615-7">Resilience of S309 and AZD7442 Monoclonal Antibody Treatments against Infection by SARS-CoV-2 Omicron Lineage Strains</a>’. <em>Nature Communications</em> 13, no. 1 (2 July 2022): 3824.</li>
  <li>Chavda, Vivek P., Riddhi Prajapati, Disha Lathigara, Bhumi Nagar, Jay Kukadiya, Elrashdy M. Redwan, Vladimir N. Uversky, Mukesh N. Kher, and Rajvi Patel. ‘<a href="https://doi.org/10.1080/14712598.2022.2078160">Therapeutic Monoclonal Antibodies for COVID-19 Management: An Update</a>’. <em>Expert Opinion on Biological Therapy</em> 22, no. 6 (June 2022): 763–80.</li>
  <li>Chen, Benjamin, Nina Haste, Nancy Binkin, Nancy Law, Lucy E. Horton, Nancy Yam, Victor Chen, and Shira Abeles. ‘<a href="https://doi.org/10.1371/journal.pone.0275356">Real World Effectiveness of Tixagevimab/Cilgavimab (Evusheld) in the Omicron Era</a>’. <em>PloS One</em> 18, no. 4 (2023): e0275356.</li>
  <li>Chollet, Vincent, Oriol Manuel, and Serge De Vallière. ‘<a href="https://doi.org/10.53738/REVMED.2022.18.802.2077">COVID-19, how to treat the disease during Fall 2022?</a>’. Revue Medicale Suisse 18, no. 802 (2 November 2022): 2077–81.</li>
  <li>Conte, William L., and Lilian Golzarri-Arroyo. 2022. ‘<a href="https://doi.org/10.1016/j.msard.2022.103905">Tixagevimab and Cilgavimab (Evusheld) Boosts Antibody Levels to SARS-CoV-2 in Patients with Multiple Sclerosis on b-Cell Depleters</a>’. <em>Multiple Sclerosis and Related Disorders</em> 63 (July): 103905.</li>
  <li>Convertino, Irma, Sara Ferraro, Emiliano Cappello, Giulia Valdiserra, Marco Bonaso, and Marco Tuccori. ‘<a href="https://doi.org/10.1080/17460441.2023.2170348">Tixagevimab + Cilgavimab against SARS-CoV-2: The Preclinical and Clinical Development and Real-World Evidence</a>’. <em>Expert Opinion on Drug Discovery</em>, 17 January 2023.</li>
  <li>Cusi, Maria Grazia, Anna Maria Di Giacomo, Gabriele Anichini, Gianni Gori Savellini, Chiara Terrosi, Claudia Gandolfo, and Michele Maio. ‘<a href="https://doi.org/10.3390/v15030614">Rational Use of Monoclonal Antibodies as Therapeutic Treatment in an Oncologic Patient with Long COVID</a>’. <em>Viruses</em> 15, no. 3 (23 February 2023): 614.</li>
  <li>Das, Nabarun Chandra, Pritha Chakraborty, Jagadeesh Bayry, and Suprabhat Mukherjee. ‘<a href="https://doi.org/10.3389/fimmu.2021.782506">In Silico Analyses on the Comparative Potential of Therapeutic Human Monoclonal Antibodies Against Newly Emerged SARS-CoV-2 Variants Bearing Mutant Spike Protein</a>’. <em>Frontiers in Immunology</em> 12 (2021): 782506.</li>
  <li>Davis, Jennifer M., and Jonathan Z. Li. ‘<a href="https://doi.org/10.1093/cid/ciac902">The Promise and Peril of Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Monoclonal Antibodies</a>’. <em>Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America</em> 76, no. 7 (3 April 2023): 1257–59.</li>
  <li>Degirmenci, Huseyin Berk, Jinseo Oh, Alison M. Bays, Jenna L. Thomason, and Jean W. Liew. ‘<a href="https://doi.org/10.7759/cureus.32684">Public Interest in COVID-19 Therapeutics for High-Risk Populations During the Omicron Era: A Google Trends Analysis</a>’. <em>Cureus</em> 14, no. 12 (December 2022): e32684.</li>
  <li>[PREPRINT] Desautels, Thomas A., Kathryn T. Arrildt, Adam T. Zemla, Edmond Y. Lau, Fangqiang Zhu, Dante Ricci, Stephanie Cronin, et al. ‘<a href="https://doi.org/10.1101/2022.10.21.513237">Computationally Restoring the Potency of a Clinical Antibody against SARS-CoV-2 Omicron Subvariants</a>’. <em>BioRxiv: The Preprint Server for Biology</em>, 24 October 2022, 2022.10.21.513237.</li>
  <li>Dippel, Andrew, Austin Gallegos, Vineela Aleti, Arnita Barnes, Xiaoru Chen, Elizabeth Christian, Jared Delmar, et al. ‘<a href="https://doi.org/10.1080/19420862.2022.2152526">Developability Profiling of a Panel of Fc Engineered SARS-CoV-2 Neutralizing Antibodies</a>’. <em>MAbs</em> 15, no. 1 (2023): 2152526.</li>
  <li>Dong, Jinhui, Seth J. Zost, Allison J. Greaney, Tyler N. Starr, Adam S. Dingens, Elaine C. Chen, Rita E. Chen, et al. ‘<a href="https://doi.org/10.1038/s41564-021-00972-2">Genetic and Structural Basis for SARS-CoV-2 Variant Neutralization by a Two-Antibody Cocktail</a>’. <em>Nature Microbiology</em> 6, no. 10 (October 2021): 1233–44.</li>
  <li>Fitzsimmons, William E. ‘<a href="https://doi.org/10.1080/21645515.2022.2068338">COVID-19 Vaccine Associated Transverse Myelitis-Evusheld as an Option When Vaccination Is Not Recommended Due to Severe Adverse Events</a>’. Human Vaccines &amp; Immunotherapeutics, 5 May 2022, 1–2.</li>
  <li>Focosi, Daniele. ‘<a href="https://doi.org/10.3390/v15051048">A Web Tool to Estimate Baseline Anti-Spike Monoclonal Antibody Efficacy Based on Regional Genomic Surveillance</a>’. <em>Viruses 15</em>, no. 5 (25 April 2023): 1048.</li>
  <li>Focosi, Daniele, and Arturo Casadevall. ‘<a href="https://doi.org/10.3390/v14091999">A Critical Analysis of the Use of Cilgavimab plus Tixagevimab Monoclonal Antibody Cocktail (Evusheld™) for COVID-19 Prophylaxis and Treatment</a>’. <em>Viruses</em> 14, no. 9 (9 September 2022): 1999.</li>
  <li>Focosi, Daniele, Fabrizio Maggi, Shmuel Shoham, and Arturo Casadevall. ‘<a href="https://doi.org/10.1002/jmv.28277">Discriminating Endogenous Vaccine-Elicited Anti-Spike Antibody Responses from Exogenous Anti-Spike Monoclonal Antibodies: The Case of Evusheld</a>’. <em>Journal of Medical Virology</em>, 3 November 2022, e28277.</li>
  <li>[PREPRINT] Focosi, Daniele, Rodrigo Quiroga, Scott A. McConnell, Marc C. Johnson, and Arturo Casadevall. ‘<a href="https://doi.org/10.1101/2022.12.05.518843">Convergent Evolution in SARS-CoV-2 Spike Creates a Variant Soup That Causes New COVID-19 Waves</a>’. <em>bioRxiv</em>, 5 December 2022.</li>
  <li>Focosi, Daniele, Rodrigo Quiroga, Scott McConnell, Marc C. Johnson, and Arturo Casadevall. ‘<a href="https://doi.org/10.3390/ijms24032264">Convergent Evolution in SARS-CoV-2 Spike Creates a Variant Soup from Which New COVID-19 Waves Emerge</a>’. <em>International Journal of Molecular Sciences</em> 24, no. 3 (23 January 2023): 2264.</li>
  <li>Focosi, Daniele, and Massimo Franchini. ‘<a href="https://doi.org/10.1016/j.transci.2023.103648">Polyclonal Immunoglobulins for COVID-19 Pre-Exposure Prophylaxis in Immunocompromised Patients</a>’. <em>Transfusion and Apheresis Science: Official Journal of the World Apheresis Association: Official Journal of the European Society for Haemapheresis</em>, 31 January 2023, 103648.</li>
  <li>Forte-Soto, Pablo, Muna Albayaty, Dennis Brooks, Rosalinda H. Arends, John Tillinghast, Anastasia A. Aksyuk, Jerome Bouquet, et al. ‘<a href="https://doi.org/10.1093/infdis/jiad014">Safety, Tolerability and Pharmacokinetics of Half-Life Extended SARS-CoV-2 Neutralizing Monoclonal Antibodies AZD7442 (Tixagevimab/Cilgavimab) in Healthy Adults</a>’. <em>The Journal of Infectious Diseases</em>, 23 January 2023, jiad014.</li>
  <li>Handlogten, Michael W., Stefanie Bosley, Sarah Dunn, Jie Zhu, Allison Lee-O’Brien, Lina Li, Jamy Therres, et al. ‘<a href="https://doi.org/10.1002/bit.28336">Accelerated Cell Culture Process Development and Characterization for Cilgavimab/Tixagevimab (AZD7442) for the Prevention and Treatment of COVID-19</a>’. <em>Biotechnology and Bioengineering</em>, 1 February 2023.</li>
  <li>Hu, Ye-Fan, Jing-Chu Hu, Hin Chu, Thomas Yau, Bao-Zhong Zhang, and Jian-Dong Huang. ‘<a href="https://doi.org/10.3390/v14020390">In-Silico Analysis of Monoclonal Antibodies against SARS-CoV-2 Omicron</a>’. <em>Viruses</em> 14, no. 2 (14 February 2022): 390.</li>
  <li>Iacobucci, Gareth. ‘<a href="https://doi.org/10.1136/bmj.o2431">Evusheld: Government Is Urged to Expedite Covid Antibody Treatment for Vulnerable Patients</a>’. <em>BMJ</em> 379 (2022): o2431.</li>
  <li>Iacobucci, Gareth. ‘<a href="https://doi.org/10.1136/bmj.o2690">Covid-19: Evusheld Protects the Most Vulnerable Patients, Analysis Shows</a>’. <em>BMJ</em> 379 (8 November 2022): o2690.</li>
  <li>Jakimovski, Dejan, Svetlana P. Eckert, Omid Mirmosayyeb, Sangharsha Thapa, Penny Pennington, David Hojnacki, and Bianca Weinstock-Guttman. ‘<a href="https://doi.org/10.3390/vaccines11020350">Tixagevimab and Cilgavimab (Evusheld™) Prophylaxis Prevents Breakthrough COVID-19 Infections in Immunosuppressed Population: 6-Month Prospective Study</a>’. <em>Vaccines</em> 11, no. 2 (2023): 350.</li>
  <li>Jondreville, Ludovic, Maud D’Aveni, Hélène Labussière-Wallet, Amandine Le Bourgeois, Alban Villate, Ana Berceanu, Silvia-Maria Bezsera, et al. ‘<a href="https://doi.org/10.1186/s13045-022-01387-0">Pre-Exposure Prophylaxis with Tixagevimab/Cilgavimab (AZD7442) Prevents Severe SARS-CoV-2 Infection in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation during the Omicron Wave: A Multicentric Retrospective Study of SFGM-TC</a>’. <em>Journal of Hematology &amp; Oncology</em> 15, no. 1 (28 November 2022): 169.</li>
  <li>Jugler, Collin, Haiyan Sun, Katherine Nguyen, Roman Palt, Mitchell Felder, Herta Steinkellner, and Qiang Chen. ‘<a href="https://doi.org/10.1111/pbi.13970">A Novel Plant-Made Monoclonal Antibody Enhances the Synergetic Potency of an Antibody Cocktail against the SARS-CoV-2 Omicron Variant</a>’. <em>Plant Biotechnology Journal</em>, 20 November 2022.</li>
  <li>[PREPRINT] Jurdi, Ayman Al, Leela Morena, Mariesa Cote, Emily Bethea, Jamil Azzi, and Leonardo V. Riella. 2022. ‘<a href="https://doi.org/10.1101/2022.05.17.22274980">Tixagevimab/Cilgavimab Pre-Exposure Prophylaxis Is Associated with Lower Breakthrough Infection Risk in Vaccinated Solid Organ Transplant Recipients during the Omicron Wave</a>’. <em>medRxiv</em>.</li>
  <li>Kaminski, Hannah, Mickael Gigan, Agathe Vermorel, Manon Charrier, Laura Guirle, Frederic Jambon, Arthur Lacapère, et al. ‘<a href="https://doi.org/10.1016/j.kint.2022.07.008">Covid-19 Morbidity Decreases with Tixagevimab/Cilgavimab Preexposure Prophylaxis in Kidney Transplant Recipients Non/Low Vaccine Responders</a>’. <em>Kidney International</em>, 20 July 2022, S0085-2538(22)00550-6.</li>
  <li>Kaplon, Hélène, Silvia Crescioli, Alicia Chenoweth, Jyothsna Visweswaraiah, and Janice M. Reichert. ‘<a href="https://doi.org/10.1080/19420862.2022.2153410">Antibodies to Watch in 2023</a>’. <em>MAbs</em> 15, no. 1 (2023): 2153410.</li>
  <li>[PREPRINT] Karaba, Andrew H., Jake D. Kim, Teresa P.-Y. Chiang, Jennifer L. Alejo, Aura T. Abedon, Jonathan Mitchell, Amy Chang, et al. ‘<a href="https://doi.org/10.1101/2022.05.24.22275467">Omicron BA.1 and BA.2 Neutralizing Activity Following Pre-Exposure Prophylaxis with Tixagevimab plus Cilgavimab in Vaccinated Solid Organ Transplant Recipients</a>’. <em>MedRxiv: The Preprint Server for Health Sciences</em>, 26 May 2022, 2022.05.24.22275467.</li>
  <li>Keam, Susan J. ‘<a href="https://doi.org/10.1007/s40265-022-01731-1">Tixagevimab + Cilgavimab: First Approval</a>’. <em>Drugs</em>, 21 June 2022.</li>
  <li>Kertes, Jennifer, Shirley Shapiro Ben David, Noya Engel-Zohar, Keren Rosen, Beatriz Hemo, Avner Kantor, Limor Adler, Naama Shamir Stein, Miri Mizrahi Reuveni, and Arnon Shahar. ‘<a href="https://doi.org/10.1093/cid/ciac625">Association between AZD7442 (Tixagevimab-Cilgavimab) Administration and SARS-CoV-2 Infection, Hospitalization and Mortality</a>’. <em>Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America</em>, 29 July 2022, ciac625.</li>
  <li>Konyak, Beyau M., Mohan Sharma, Shabnam Kharia, Ramendra Pati Pandey, and Chung-Ming Chang. ‘<a href="https://doi.org/10.3390/vaccines10091468">A Systematic Review on the Emergence of Omicron Variant and Recent Advancement in Therapies</a>’. <em>Vaccines</em> 10, no. 9 (5 September 2022): 1468.</li>
  <li>Kotton, Camille N. ‘<a href="https://doi.org/10.7326/M22-1026">Belt and Suspenders: Vaccines and Tixagevimab/Cilgavimab for Prevention of COVID-19 in Immunocompromised Patients</a>’. <em>Annals of Internal Medicine</em>, 12 April 2022.</li>
  <li>Lamballerie, Xavier de, Guillaume Martin-Blondel, Axelle Dupont, Jacques Izopet, France Mentré, Nassim Kamar, Brigitte Autran, et al. ‘<a href="https://doi.org/10.1016/j.jinf.2022.10.006">Low Serum Neutralization of Omicron Variants a Month after AZD7442 Prophylaxis Initiation</a>’. <em>The Journal of Infection</em>, 8 October 2022, S0163-4453(22)00565-5.</li>
  <li>Lee, Lennard, Keeley Bernhardt, Antonio Pagliuca, and Alex Richter. ‘<a href="https://www.bmj.com/content/378/bmj.o2021/rr">Abandoning the Winter 2022 Protection for the Immunocompromised - a Highly Irregular, Uncomfortable Decision for a Vulnerable Group That We Are Likely to Regret</a>.’ <em>BMJ</em>, no. 2022;378:o2021 (22 August 2022).</li>
  <li>Levin, Myron J., Andrew Ustianowski, Stéphane De Wit, Odile Launay, Miles Avila, Alison Templeton, Yuan Yuan, et al. ‘<a href="https://doi.org/10.1056/NEJMoa2116620">Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19</a>’. The <em>New England Journal of Medicine</em> 386, no. 23 (9 June 2022): 2188–2200.</li>
  <li>Levin, Myron J., Andrew Ustianowski, Steven Thomas, Alison Templeton, Yuan Yuan, Seth Seegobin, Catherine F. Houlihan, et al. ‘<a href="https://doi.org/10.1093/cid/ciac899">AZD7442 (Tixagevimab/Cilgavimab) for Post-Exposure Prophylaxis of Symptomatic COVID-19</a>’. <em>Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America</em>, 22 November 2022, ciac899.</li>
  <li>Loo, Yueh-Ming, Patrick M. McTamney, Rosalinda H. Arends, Michael E. Abram, Anastasia A. Aksyuk, Seme Diallo, Daniel J. Flores, et al. ‘<a href="https://doi.org/10.1126/scitranslmed.abl8124">The SARS-CoV-2 Monoclonal Antibody Combination, AZD7442, Is Protective in Nonhuman Primates and Has an Extended Half-Life in Humans</a>’. <em>Science Translational Medicine</em> 14, no. 635 (9 March 2022): eabl8124.</li>
  <li>Mahase, Elisabeth. ‘<a href="https://doi.org/10.1136/bmj.n2860">Covid-19: AstraZeneca Says Its Antibody Drug AZD7442 Is Effective for Preventing and Reducing Severe Illness</a>’. <em>BMJ (Clinical Research Ed.)</em> 375 (19 November 2021): n2860.</li>
  <li>Mahase, Elisabeth. ‘<a href="https://doi.org/10.1136/bmj.p387">Covid-19: Evusheld Is Unlikely to Prevent Infection with Current or Future Variants, NICE Concludes</a>’. <em>BMJ (Clinical Research Ed.)</em> 380 (16 February 2023): 387.</li>
  <li>Maselkar, Sheetal, Alexandre Kiazand, Alison Templeton, Hugh Montgomery, and Mark T. Esser. ‘<a href="https://doi.org/10.1016/S2213-2600(22)00450-7">Cardiac and Vascular Serious Adverse Events Following Tixagevimab-Cilgavimab - Author’s Reply</a>’. The Lancet. Respiratory Medicine, 12 December 2022, S2213-2600(22)00450-7.</li>
  <li>Mu, Ruipeng, Yue Huang, Jerome Bouquet, Jiaqi Yuan, Robert J. Kubiak, Eric Ma, Sami Naser, et al. ‘<a href="https://doi.org/10.1021/acs.analchem.2c01320">Multiplex Hybrid Antigen-Capture LC-MRM Quantification in Sera and Nasal Lining Fluid of AZD7442, a SARS-CoV-2-Targeting Antibody Combination</a>’. <em>Analytical Chemistry</em>, 21 October 2022.</li>
  <li>Mu, Ruipeng, Yue Huang, Jerome Bouquet, Jiaqi Yuan, Robert J. Kubiak, Eric Ma, Sami Naser, et al. ‘<a href="https://doi.org/10.1021/acs.analchem.2c01320">Multiplex Hybrid Antigen-Capture LC-MRM Quantification in Sera and Nasal Lining Fluid of AZD7442, a SARS-CoV-2-Targeting Antibody Combination</a>’. <em>Analytical Chemistry</em> 94, no. 43 (1 November 2022): 14835–45.</li>
  <li>Najjar-Debbiny, Ronza, Naomi Gronich, Gabriel Weber, Nili Stein, and Walid Saliba. ‘<a href="https://doi.org/10.1093/cid/ciac855">Effectiveness of Evusheld in Immunocompromised Patients: Propensity Score-Matched Analysis</a>’. <em>Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America</em>, 31 October 2022, ciac855.</li>
  <li>NHS England RAPID-C19. 2022. ‘<a href="https://www.gov.uk/government/publications/higher-risk-patients-eligible-for-covid-19-treatments-independent-advisory-group-report/defining-the-highest-risk-clinical-subgroups-upon-community-infection-with-sars-cov-2-when-considering-the-use-of-neutralising-monoclonal-antibodies">Defining the Highest-Risk Clinical Subgroups upon Community Infection with SARS-CoV-2 When Considering the Use of Neutralising Monoclonal Antibodies (NMABs) and Antiviral Drugs: Independent Advisory Group Report</a>’. <em>GOV.UK</em>. 30 May 2022.</li>
  <li>Nguyen, Yann, Adrien Flahault, Nathalie Chavarot, Cléa Melenotte, Morgane Cheminant, Paul Deschamps, Nicolas Carlier, et al. ‘<a href="https://doi.org/10.1016/j.cmi.2022.07.015">Pre-Exposure Prophylaxis with Tixagevimab and Cilgavimab (Evusheld©) for COVID-19 among 1112 Severely Immunocompromised Patients</a>’. <em>Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases</em>, 1 August 2022, S1198-743X(22)00383-4.</li>
  <li>Ocon, Anthony J., and S. Shahzad Mustafa. ‘<a href="https://doi.org/10.1097/RHU.0000000000001907">Real-World Experience of Tixagevimab and Cilgavimab (Evusheld) in Rheumatologic Patients on Rituximab</a>’. <em>JCR: Journal of Clinical Rheumatology</em>, 20 September 2022.</li>
  <li>Odriozola Herrán, Aitor, José Ignacio Fortea Ormaechea, Antonio Cuadrado, Ángela Puente Sánchez, Jeffrey V. Lazarus, Javier Crespo, and Emilio Fábrega. ‘<a href="https://doi.org/10.17235/reed.2022.9058/2022">Protective Measures against Omicron Could Be More Effective than Evusheld® in Liver Transplant Recipients</a>’. <em>Revista Espanola De Enfermedades Digestivas: Organo Oficial De La Sociedad Espanola De Patologia Digestiva</em> 114, no. 12 (December 2022): 769–70.</li>
  <li>Pawankar, Ruby, Bernard Yu-Hor Thong, Marysia Tiongco-Recto, Jiu-Yao Wang, Amir Hamzah Abdul Latiff, Ting Fan Leung, Philip Hei Li, et al. ‘<a href="https://doi.org/10.1111/cea.14191">Asia Pacific Perspectives on the Second Year of the COVID-19 Pandemic: A Follow-up Survey</a>’. <em>Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology</em> 52, no. 8 (August 2022): 965–73.</li>
  <li>Piszczek, Jolanta, Srinivas Murthy, and Kevin Afra. ‘<a href="https://doi.org/10.1016/S2213-2600(22)00452-0">Cardiac and Vascular Serious Adverse Events Following Tixagevimab–Cilgavimab</a>’. <em>The Lancet Respiratory Medicine</em>, 12 December 2022.</li>
  <li>[PREPRINT] Planas, Delphine, Timothee Bruel, Isabelle Staropoli, Florence Guivel-Benhassine, Francoise Porrot, Piet Maes, Ludivine Grzelak, et al. ‘<a href="https://doi.org/10.1101/2022.11.17.516888">Resistance of Omicron Subvariants BA.2.75.2, BA.4.6 and BQ.1.1 to Neutralizing Antibodies</a>’. <em>BioRxiv: The Preprint Server for Biology</em>, 21 November 2022, 2022.11.17.516888.</li>
  <li>Planas, Delphine, Timothée Bruel, Isabelle Staropoli, Florence Guivel-Benhassine, Françoise Porrot, Piet Maes, Ludivine Grzelak, et al. ‘<a href="https://doi.org/10.1038/s41467-023-36561-6">Resistance of Omicron Subvariants BA.2.75.2, BA.4.6, and BQ.1.1 to Neutralizing Antibodies</a>’. <em>Nature Communications</em> 14, no. 1 (14 February 2023): 824.</li>
  <li>Rattanavipapong, Waranya, Chittawan Poonsiri, Wanrudee Isaranuwatchai, Sopon Iamsirithaworn, Jutarat Apakupakul, Chaninan Sonthichai, Rungrueng Kitphati, and Yot Teerawattananon. ‘<a href="https://doi.org/10.1007/s40258-023-00796-7">Economic Evaluation of Evusheld for Preexposure Prevention of COVID-19 in High-Risk Populations: Early Evidence from Thailand</a>’. <em>Applied Health Economics and Health Policy</em>, 16 March 2023, 1–12.</li>
  <li>Roe, Tiffany L., Tyler Brady, Nicolette Schuko, Amy Nguyen, Jagadish Beloor, Johnathan D. Guest, Anastasia A. Aksyuk, et al. ‘<a href="https://doi.org/10.1128/spectrum.00333-23">Molecular Characterization of AZD7442 (Tixagevimab-Cilgavimab) Neutralization of SARS-CoV-2 Omicron Subvariants</a>’. <em>Microbiology Spectrum</em>, 2023, e0033323.</li>
  <li>Shaikh, Suhail A., Faiza Morado, Pnada Kawewat-Ho, Rachel Cartus, Roland Davoudi, Kevin Forrester, Krist Azizian, Emily Blodget, Thin Thin Maw, and Neha Nanda. ‘<a href="https://doi.org/10.1111/ctr.14661">Tixagevimab-Cilgavimab: Utilization in the Solid Organ Transplant Population</a>’. <em>Clinical Transplantation</em> 36, no. 6 (June 2022): e14661.</li>
  <li>Shields, Adrian M, Ariharan Anantharachagan, Gururaj Arumugakani, Kenneth Baker, Sameer Bahal, Helen Baxendale, William Bermingham, et al. 2022. ‘<a href="https://doi.org/10.1093/cei/uxac008">Outcomes Following SARS-CoV-2 Infection in Patients with Primary and Secondary Immunodeficiency in the UK</a>’. <em>Clinical and Experimental Immunology</em>, January, uxac008.</li>
  <li>Singson, Jason Robert C., Pam Daily Kirley, Huong Pham, Gretchen Rothrock, Isaac Armistead, James Meek, Evan J. Anderson, et al. ‘<a href="https://doi.org/10.15585/mmwr.mm7127a3">Factors Associated with Severe Outcomes Among Immunocompromised Adults Hospitalized for COVID-19 - COVID-NET, 10 States, March 2020-February 2022</a>’. MMWR. Morbidity and Mortality Weekly Report 71, no. 27 (8 July 2022): 878–84.</li>
  <li>Squire, Jacqueline D., Mitchell M. Pitlick, Catherine M. Freeman, and Avni Y. Joshi. ‘<a href="https://doi.org/10.1016/j.jacig.2023.100081">Safety and Tolerability of Evusheld in CVID Patients: The Mayo Clinic Experience</a>’. <em>The Journal of Allergy and Clinical Immunology</em>. Global, 8 February 2023, 100081.</li>
  <li>Stuver, Robert, Gunjan L. Shah, Neha S. Korde, Lindsey E. Roeker, Anthony R. Mato, Connie L. Batlevi, David J. Chung, et al. 2022. ‘<a href="https://doi.org/10.1016/j.ccell.2022.05.007">Activity of AZD7442 (Tixagevimab-Cilgavimab) against Omicron SARS-CoV-2 in Patients with Hematologic Malignancies</a>’. <em>Cancer Cell</em>, May.</li>
  <li>Montgomery, Hugh, F. D. Richard Hobbs, Francisco Padilla, Douglas Arbetter, Alison Templeton, Seth Seegobin, Kenneth Kim, et al. 2022. ‘<a href="https://doi.org/10.1016/S2213-2600(22)00180-1">Efficacy and Safety of Intramuscular Administration of Tixagevimab–Cilgavimab for Early Outpatient Treatment of COVID-19 (TACKLE): A Phase 3, Randomised, Double-Blind, Placebo-Controlled Trial</a>’. <em>The Lancet Respiratory Medicine</em>.</li>
  <li>Tada, Takuya, Hao Zhou, Belinda M. Dcosta, Marie I. Samanovic, Vidya Chivukula, Ramin S. Herati, Stevan R. Hubbard, Mark J. Mulligan, and Nathaniel R. Landau. ‘<a href="https://doi.org/10.1016/j.ebiom.2022.103944">Increased Resistance of SARS-CoV-2 Omicron Variant to Neutralization by Vaccine-Elicited and Therapeutic Antibodies</a>’. <em>EBioMedicine</em> 78 (April 2022): 103944.</li>
  <li>Takashita, Emi, Seiya Yamayoshi, Viviana Simon, Harm van Bakel, Emilia M. Sordillo, Andrew Pekosz, Shuetsu Fukushi, et al. ‘<a href="https://doi.org/10.1056/NEJMc2207519">Efficacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants</a>’. <em>New England Journal of Medicine</em>, 20 July 2022.</li>
  <li>Touret, Franck, Cécile Baronti, Hawa Sophia Bouzidi, and Xavier de Lamballerie. ‘<a href="https://doi.org/10.1038/s41598-022-08559-5">In Vitro Evaluation of Therapeutic Antibodies against a SARS-CoV-2 Omicron B.1.1.529 Isolate</a>’. <em>Scientific Reports</em> 12, no. 1 (18 March 2022): 4683.</li>
  <li>Touret, Franck, Cécile Baronti, Boris Pastorino, Paola Mariela Saba Villarroel, Laetitia Ninove, Antoine Nougairède, and Xavier de Lamballerie. ‘<a href="https://doi.org/10.1038/s41598-022-16964-z">In Vitro Activity of Therapeutic Antibodies against SARS-CoV-2 Omicron BA.1, BA.2 and BA.5</a>’. <em>Scientific Reports</em> 12, no. 1 (23 July 2022): 12609.</li>
  <li>Touret, Franck, Guillaume Martin-Blondel, Xavier de Lamballerie, Axelle Dupont, Jacques Izopet, France Mentré, Nassim Kamar, et al. ‘<a href="https://doi.org/10.1016/j.jinf.2023.02.002">Low to Undetectable Omicron BQ.1.1 Neutralization by Patient’s Sera a Month after Initiation of AZD7442 600 Mg</a>’. <em>The Journal of Infection</em>, 5 February 2023, S0163-4453(23)00071-3.</li>
  <li>Touret, Franck, Emilie Giraud, Jérôme Bourret, Flora Donati, Jaouen Tran-Rajau, Jeanne Chiaravalli, Frédéric Lemoine, et al. ‘<a href="https://doi.org/10.1016/j.isci.2023.106413">Enhanced Neutralization Escape to Therapeutic Monoclonal Antibodies by SARS-CoV-2 Omicron Sub-Lineages</a>’. <em>IScience</em> 26, no. 4 (21 April 2023): 106413.</li>
  <li>[PREPRINT] Tuekprakhon, Aekkachai, Jiandong Huo, Rungtiwa Nutalai, Aiste Dijokaite-Guraliuc, Daming Zhou, Helen M. Ginn, Muneeswaran Selvaraj, et al. 2022. ‘<a href="https://doi.org/10.1101/2022.05.21.492554">Further Antibody Escape by Omicron BA.4 and BA.5 from Vaccine and BA.1 Serum</a>’. <em>bioRxiv</em>.</li>
  <li>Whelan, Mary Grace, Leah Santacroce, Lucy Masto, Grace Qian, Emily Kowalski, Kathleen Vanni, Sanjat Kanjilal, Michael E. Weinblatt, Jeffrey A. Sparks, and Sara K. Tedeschi. ‘<a href="https://doi.org/10.1007/s10067-023-06512-z">Predictors of Low Spike Antibody Response in Patients with Systemic Rheumatic Disease after an Initial Course of COVID-19 Vaccination</a>’. <em>Clinical Rheumatology</em>, 19 January 2023, 1–6.</li>
  <li>Willicombe, Michelle, Miranda Scanlon, Fiona Loud, and Liz Lightstone. 2022. ‘<a href="https://doi.org/10.1136/bmj.o966">Should We Be Clinically Assessing Antibody Responses to Covid Vaccines in Immunocompromised People?</a>’ <em>BMJ</em> 377 (April): o966.</li>
  <li>Wise, Jacqui. ‘<a href="https://doi.org/10.1136/bmj.o722">Covid-19: Evusheld Is Approved in UK for Prophylaxis in Immunocompromised People</a>’. <em>BMJ (Clinical Research Ed.)</em> 376 (17 March 2022): o722.</li>
  <li>Wu, Mary Y., Edward J. Carr, Ruth Harvey, Harriet V. Mears, Svend Kjaer, Hermaleigh Townsley, Agnieszka Hobbs, et al. ‘<a href="https://doi.org/10.1016/S0140-6736(22)01938-9">WHO’s Therapeutics and COVID-19 Living Guideline on MAbs Needs to Be Reassessed</a>’. <em>The Lancet</em> (6 October 2022).</li>
  <li>[PREPRINT] Yamasoba, Daichi, Izumi Kimura, Yusuke Kosugi, Keiya Uriu, Shigeru Fujita, Jumpei Ito, Kei Sato, and The Genotype to Phenotype Japan (G2P-Japan) Consortium. ‘<a href="https://doi.org/10.1101/2022.07.14.500041">Neutralization Sensitivity of Omicron BA.2.75 to Therapeutic Monoclonal Antibodies</a>’. <em>bioRxiv</em>, 15 July 2022.</li>
  <li>Yamasoba, Daichi, Yusuke Kosugi, Izumi Kimura, Shigeru Fujita, Keiya Uriu, Jumpei Ito, and Kei Sato. 2022. ‘<a href="https://doi.org/10.1016/S1473-3099(22)00365-6">Neutralisation Sensitivity of SARS-CoV-2 Omicron Subvariants to Therapeutic Monoclonal Antibodies</a>’. <em>The Lancet Infectious Diseases</em>.</li>
  <li>Yang, Jinyoung, Gunho Won, Jin Yang Baek, Young Ho Lee, Haein Kim, Kyungmin Huh, Sun Young Cho, et al. ‘<a href="https://doi.org/10.3389/fimmu.2023.1139980">Neutralizing Activity against Omicron BA.5 after Tixagevimab/Cilgavimab Administration Comparable to Those after Omicron BA.1/BA.2 Breakthrough Infections</a>’. <em>Frontiers in Immunology</em> 14 (2023): 1139980.</li>
  <li>[PREPRINT] Young-Xu, Yinong, Lauren Epstein, Vincent C. Marconi, Victoria Davey, Gabrielle Zwain, Jeremy Smith, Caroline Korves, Fran Cunningham, Robert Bonomo, and Adit A. Ginde. 2022. ‘<a href="https://doi.org/10.1101/2022.05.28.22275716">Tixagevimab/Cilgavimab for Prevention of COVID-19 during the Omicron Surge: Retrospective Analysis of National VA Electronic Data</a>’. <em>medRxiv</em>.</li>
</ul>

<h2 id="secondary-references">Secondary References</h2>
<p>This secondary bibliography presents a selection of references on topics not directly related to Evusheld but that are of interest (e.g. the mental health implications of shielding).</p>

<ul>
  <li>Daniels, Jo, and Hannah Rettie. ‘<a href="https://doi.org/10.3390/ijerph19127333">The Mental Health Impact of the COVID-19 Pandemic Second Wave on Shielders and Their Family Members</a>’. International Journal of Environmental Research and Public Health 19, no. 12 (January 2022): 7333.</li>
</ul>

<h2 id="events">Events</h2>
<ul>
  <li>AstraZeneca. 2022. ‘<a href="https://www.politico.eu/event/the-unmet-needs-of-immunocompromised-patients-post-covid-19/">The Unmet Needs of Immunocompromised Patients Post-COVID 19</a>’. <em>POLITICO</em>. 9 June 2022.</li>
</ul>

<h2 id="media">Media</h2>

<iframe src="https://player.vimeo.com/video/719537557?h=78adcb4cb9" width="640" height="480" frameborder="0" allow="autoplay; fullscreen; picture-in-picture" allowfullscreen=""></iframe>
<p><a href="https://vimeo.com/719537557">BBC News - 3pm - 21 February 2022</a> from <a href="https://vimeo.com/shannonleebanks">Shannon Banks</a> on <a href="https://vimeo.com">Vimeo</a>.</p>

<iframe width="560" height="315" src="https://www.youtube.com/embed/Xstee16fIPE" title="YouTube video player" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture" allowfullscreen=""></iframe>

<iframe src="https://player.vimeo.com/video/733719996?h=0be83c25e6" width="640" height="480" frameborder="0" allow="autoplay; fullscreen; picture-in-picture" allowfullscreen=""></iframe>
<p><a href="https://vimeo.com/733719996">Channel 5 News - 5pm - 12 July 2022</a> from <a href="https://vimeo.com/shannonleebanks">Shannon Banks</a> on <a href="https://vimeo.com">Vimeo</a>.</p>

<iframe src="https://player.vimeo.com/video/733719643?h=2563d6c38b" width="640" height="480" frameborder="0" allow="autoplay; fullscreen; picture-in-picture" allowfullscreen=""></iframe>
<p><a href="https://vimeo.com/733719643">ITV News - 6:30pm - 26 July</a> from <a href="https://vimeo.com/shannonleebanks">Shannon Banks</a> on <a href="https://vimeo.com">Vimeo</a>.</p>

        </div>
    </div>

    <!-- Footer -->
	<footer id="footer">
		<div class="inner">
			<ul class="icons">
				
					
				
					
				
					
				
					
				
					
				
					
						<li>
							<a href="https://twitter.com/evusheld4theuk" class="icon alt fa-twitter" target="_blank" rel="noopener noreferrer" aria-label="Twitter">
								<span class="label">Twitter</span>
							</a>
						</li>
					
				
					
						<li>
							<a href="https://www.facebook.com/groups/692949675108155" class="icon alt fa-facebook" target="_blank" rel="noopener noreferrer" aria-label="Facebook">
								<span class="label">Facebook</span>
							</a>
						</li>
					
				
					
				

				<li>
					<a href="mailto:martin@eve.gd" class="icon alt fa-solid fa-envelope" target="_blank" rel="noopener noreferrer" aria-label="Email">
						<span class="label">Email</span>
					</a>
				</li>
			</ul>
			<ul class="copyright">
				<li>&copy; Forgotten Lives UK A Patient Campaigning Group</li>
				<li>Design: <a href="https://html5up.net" target="_blank">HTML5 UP</a></li>
				<li>Jekyll integration: <a href="http://andrewbanchi.ch" target="_blank">Andrew Banchich</a></li>

			</ul>
		</div>
	</footer>

</div>

<!-- Scripts -->
	<script src="https://forgottenlives.uk/assets/js/jquery.min.js"></script>
	<script src="https://forgottenlives.uk/assets/js/jquery.scrolly.min.js"></script>
	<script src="https://forgottenlives.uk/assets/js/jquery.scrollex.min.js"></script>
	<script src="https://forgottenlives.uk/assets/js/skel.min.js"></script>
	<script src="https://forgottenlives.uk/assets/js/util.js"></script>
	<!--[if lte IE 8]><script src="https://forgottenlives.uk/assets/js/ie/respond.min.js"></script><![endif]-->
	<script src="https://forgottenlives.uk/assets/js/main.js"></script>


</body>

</html>
